98
lactation in women with autoimmune and systemic inflammatory diseases. Arthritis Care Res.
2015;67:313–25.- Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine or combination therapy
for Crohn’s disease. N Engl J Med. 2010;362:1383–95. - Van Assche G, Madelaine-Beuzelin C, D’Haens G, et al. Withdrawal of immunosuppres-
sion in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial.
Gastroenterology. 2008;134:1861–8. - Torres J, Boyapati RK, Kennedy NA, et al. Systematic review of effects of withdrawal of
immunomodulators or biologic agents from patients with inflammatory bowel disease.
Gastroenterology. 2015;149:1716–30. - Guiddir T, Fremond MC, Triki TB, et al. Anti-TNF-a therapy may cause neonatal neuropenia.
Pediatrics. 2014;134:e1189–93. - Mahadevan U, Martin CF, Dubinsky M, et al. Exposure to anti-TNFα therapy in the third
trimester of pregnancy is not associated with increased adverse outcomes: results from the
PIANO registry. Gastroenterology. 2014;146:S–170. - Sheibani S, Cohen R, Kane S, et al. The effect of maternal peripartum anti-TNFa use on infant
immune response. Dig Dis Sci. 2016;61:1622–7. - Carter JD, Ladhani A, Vasey FB. Tumor necrosis factor inhibition and VATER association: a
causal relationship. J Rheumatol. 2006;33:1014–7. - Carter JD, Ladhani A, Ricca LR, et al. A safety assessment of TNF antagonists during preg-
nancy: a review of the FDA database. J Rheumatol. 2009;36:635–41. - Crijns HJMJ, Jentink J, Garne E, et al. The distribution of congenital anomalies within the
VACTERL association among tumor necrosis factor antagonist-exposed pregnancies is similar
to the general population. J Rheumatol. 2011;38:1871–4. - Bröms G, Granath F, Ekbom A, et al. Low risk of birth defects for infants whose mothers are
treated with anti-tumor necrosis factor agents during pregnancy. Clin Gastroenterol Hepatol.
2016;14:234–41. - Bortlik M, Duricova D, Machkova N, et al. Impact of anti-tumor necrosis factor alpha antibod-
ies administered to pregnant women with inflammatory bowel diease on long-term outcome of
exposed children. Inflamm Bowel Dis. 2014;20:495–501. - Mahadevan U, Martin CF, Chambers C, et al. Achievement of developmental milestones among
offspring of women with inflammatory bowel disease: the PIANO Registry. Gastroenterology.
2014;146:S–1. - Wehner NG, Shopp G, Rocca MS, Clarke J. Effects of natalizumab, an alpha4 integrin inhibi-
tor, on the development of Hartley guinea pigs. Birth Defects Res B Dev Reprod Toxicol.
2009;86(2):98–107. - Wehner NG, Shopp G, Osterburg I, et al. Postnatal development in cynomolgus monkeys
following prenatal exposure to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res.
2009;86:144–56. - Bayas A, Penzien J, Helwigg K. Accidental natalizumab administration to the third tri-
mester of pregnancy in an adolescent patient with multiple sclerosis. Acta Neurol Scand.
2011;124:290–2. - Hoevenaren IA, de Vries LC, Rijnders RJP, Lotgering FK. Delivery of healthy babies after natal-
izumab use for multiple sclerosis: a report of two cases. Acta Neurol Scand. 2011;123:430–3. - Theaudin M, Elefant E, Senat MV. Natalizumab continuation during pregnancy in a patient
with previous severe IRIS syndrome. J Neurol Sci. 2015;359:211–2012. - Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study
in 35 accidental pregnancies during natalizumab treatment. Mult Scler. 2011;17(8):958–63. - Mahadevan U, Nazareth M, Cristiano L, et al. Natalizumab use in pregnancy. Am
J Gastroenterol. 2008;103:s449. - Cristiano L, Friend S, Bozic C, Bloomgren G. Evaluation of pregnancy outcomes from the
Tysabri(R) (Natalizumab) Pregnancy Exposure Registry. Neurology. 2013;80:P02–127. - Haghikia A, Langer-Gould A, Reliensmann G, et al. Natalizumab use during the third trimester
of pregnancy. JAMA Neurol. 2014;71(7):891–5.
J.K.J. Gaidos and S.V. Kane